|Application ||IHC, IF, FC|
|Other Accession||909, 1309|
|Isotype||Mouse / IgG1, kappa|
|Other Names||T-cell surface glycoprotein CD1a, T-cell surface antigen T6/Leu-6, hTa1 thymocyte antigen, CD1a, CD1A|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CD1a / HTA1 (Mature Langerhans Cells Marker) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells.|
|Cellular Location||Cell membrane; Single- pass type I membrane protein. Membrane raft; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Note=Subject to intracellular trafficking between the cell membrane and endosomes (PubMed:11231314). Localizes to cell surface lipid rafts (PubMed:18178838).|
|Tissue Location||Expressed on cortical thymocytes, epidermal Langerhans cells, dendritic cells, on certain T-cell leukemias, and in various other tissues.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. ĀWhen combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).Ā
McNally, AK. et al. 2011. Exp. Mol. Pathol. 91: 673-681. | Matsuda, A. et al. 2009. Invest. Ophthalmol. Vis. Sci. 50: 2871-2877. | Gulubova, M. et al. 2008. Clin. Exp. Metastasis. 25: 777-785. | Cassaday, RD. et al. 2007. Clin. Cancer Res. 13: 540-549. |
If you have any additional inquiries please email technical services at firstname.lastname@example.org.